問卷

TPIDB > Search Result

Search Result

篩選

List

184Cases

2016-05-01 - 2021-04-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2026-01-15 - 2043-05-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2030-07-16

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-05-01 - 2028-02-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-10-01 - 2016-09-12

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-10-01 - 2014-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Pracinostat

Participate Sites
9Sites

Terminated7Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors
  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Venetoclax (ABT-199)

Participate Sites
5Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2021-11-01 - 2022-08-29

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites